Perseus Proteomics, Inc. (JP:4882) has released an update.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Perseus Proteomics, Inc. has announced that the Phase I clinical trial results of their anti-transferrin receptor 1 antibody, PPMX-T003, for polycythemia vera patients will be presented at the upcoming ASH Annual Meeting. This antibody aims to control red blood cell proliferation by inhibiting iron uptake, and shows potential for treating certain cancers. Perseus Proteomics continues to advance its therapeutic antibody pipeline, including PPMX-T002 and PPMX-T004.
For further insights into JP:4882 stock, check out TipRanks’ Stock Analysis page.